Skip to main content

Table 2 Anti-HCV positive patients with and without serum autoantibodies (ANA, SMA, ANCA, AMA) – comparison of demographic variables, clinical, and biochemical parameters.

From: The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C

 

Autoantibody-negative (n = 42)

p****

Autoantibody-positive (n = 36)

Gender (m/f)

16/26

0.81

15/21

Age (yrs)*

46.1 ± 12.6

0.25

42.9 ± 12.2

HCV genotype

   

Genotype 1 and 4

24

0.57

22

Genotypes 2 and 3/ not detected

18

 

14

HCV-RNA (copies/ml)*

4.1 × 105 ± 5.5 × 105

0.007

9.1 × 105 ± 9.6 × 105

ALT (U/l)*

27.4 ± 25.0

0.006

47.5 ± 36.3

AST (U/l)*

21.5 ± 26.9

0.11

33.2 ± 35.9

Albumin (g/l)*

46.0 ± 8.3

0.16

43.8 ± 4.8

IgG (g/l)*

13.9 ± 3.1

0.08

15.4 ± 4.0

IgM (g/l)*

2.1 ± 0.9

0.69

2.2 ± 2.0

IgA (g/l)*

1.4 ± 0.8

0.23

1.8 ± 1.7

IgG to CMV (pos / neg)***

22 / 11

0.44

17 / 14

IgG to EBV (pos / neg)***

28 / 5

0.99

28 / 4

Histological score**

1.4 ± 0.8

0.62

1.5 ± 0.6

Interferon-α treatment [n (%)]

27 (64%)

0.64

21 (58%)

  1. *Mean ± SD, **Necro-inflammatory activity in liver biopsy were graded from 0 (no activity) to 4 (severe activitiy), ***IgG antibodies to cytomegaly virus and Ebstein-Barr virus were determined by ELISA, ****p-values were calculated by Fisher's exact test or Student's t test where appropriate
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us